Cargando…

Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling

Fibroblast growth factor receptor 2 (FGFR2) was demonstrated to correlate to the progression and prognosis of intrahepatic cholangiocarcinoma (ICC) by numerous evidences. However, as a well‐recognized suppressor of FGFR2 signalling, the clinical significance of Sprouty (SPRY) family of ICC has not b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yun‐Fei, Liu, Hong‐Da, Liu, Zeng‐Li, Pan, Chang, Yang, Xiao‐Qing, Ning, Shang‐Lei, Zhang, Zong‐Li, Guo, Sen, Yu, Jin‐Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201365/ https://www.ncbi.nlm.nih.gov/pubmed/30160357 http://dx.doi.org/10.1111/jcmm.13833

Ejemplares similares

Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression
por: Xu, Yunfei, et al.
Publicado: (2016)

Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle
por: Qiu, Bo, et al.
Publicado: (2019)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2021)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
por: Zhang, Lei, et al.
Publicado: (2023)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma
por: Ning, Shanglei, et al.
Publicado: (2018)

Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
por: Lidsky, Michael E., et al.
Publicado: (2022)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
por: Salati, Massimiliano, et al.
Publicado: (2021)

Diabetes and PKM2 affect prognosis in patients with intrahepatic cholangiocarcinoma
por: Fu, Kui, et al.
Publicado: (2020)

Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
por: Peng, Min, et al.
Publicado: (2023)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Effect of age on the prognosis of intrahepatic cholangiocarcinoma
por: Kim, Jung Hun, et al.
Publicado: (2023)

A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma
por: Chu, Zhenzhen, et al.
Publicado: (2023)

The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma—unveiling the future challenges in drug therapy
por: Nishida, Naoshi
Publicado: (2023)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Hypoxia inducible factors regulate the transcription of the sprouty2 gene and expression of the sprouty2 protein
por: Gao, Xianlong, et al.
Publicado: (2017)

Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular‐cholangiocarcinoma after resection
por: Song, Peipei, et al.
Publicado: (2019)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma
por: Xu, Linping, et al.
Publicado: (2022)

Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma
por: Sha, Meng, et al.
Publicado: (2019)

High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2021)

Personalized intrahepatic cholangiocarcinoma prognosis prediction using radiomics: Application and development trend
por: Chen, Pengyu, et al.
Publicado: (2023)

Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma
por: Liu, Lingyun, et al.
Publicado: (2018)

Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2017)

Flotillin-2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma
por: Xu, Zhiying, et al.
Publicado: (2020)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

Overexpression of the X-linked ribosomal protein S4 predicts poor prognosis in patients with intrahepatic cholangiocarcinoma
por: Kuang, Jie, et al.
Publicado: (2017)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis
por: Chen, Yan, et al.
Publicado: (2018)

The influence of the extent of lymph node metastasis on the prognosis for patients with intrahepatic cholangiocarcinoma
por: Wang, Jianping, et al.
Publicado: (2023)

In situ Detecting Lipids as Potential Biomarkers for the Diagnosis and Prognosis of Intrahepatic Cholangiocarcinoma
por: Li, Jiayi, et al.
Publicado: (2022)

Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype
por: Zou, Yining, et al.
Publicado: (2023)

A novel model for predicting the prognosis of postoperative intrahepatic cholangiocarcinoma patients
por: Lv, Yinghao, et al.
Publicado: (2023)

The focus clinical research in intrahepatic cholangiocarcinoma
por: Song, Yinghui, et al.
Publicado: (2022)

Expression of novel tumor markers of pancreatic adenocarcinomas in intrahepatic cholangiocarcinomas
por: Zong, Meijuan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_papmtcn7m6elnt21i812ajo5s8